CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: September 18, 2009
Result type: Reports
Project Number: SR0176-000
Product Line: Reimbursement Review

Generic Name: Eculizumab

Brand Name: Soliris

Manufacturer: Alexion Pharmaceuticals Inc.

Therapeutic Area: Paroxysmal nocturnal hemoglobinuria (PNH)

Indications: Paroxysmal nocturnal hemoglobinuria (PNH)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: February 18, 2010

Recommendation Type: Do not list